PE20181400A1 - Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab - Google Patents
Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumabInfo
- Publication number
- PE20181400A1 PE20181400A1 PE2018001077A PE2018001077A PE20181400A1 PE 20181400 A1 PE20181400 A1 PE 20181400A1 PE 2018001077 A PE2018001077 A PE 2018001077A PE 2018001077 A PE2018001077 A PE 2018001077A PE 20181400 A1 PE20181400 A1 PE 20181400A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- aqueous pharmaceutical
- formulation
- sequence
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE ANTICUERPO FARMACEUTICA ACUOSA QUE COMPRENDE: A) AVELUMAB EN UNA CONCENTRACION DE 1 MG/ML A 30 MG/ML CUYA SECUENCIA DE CADENA PESADA ES LA SEC ID NO: 1 O SEC ID NO: 2, Y LA SECUENCIA DE CADENA LIGERA ES LA SEC ID NO: 3; B) ACETATO O HISTIDINA EN UNA CONCENTRACION DE 5 mM A 15 mM COMO AGENTE AMORTIGUADOR; C) D-MANITOL O TREHALOSA EN UNA CONCENTRACION DE 240 mM A 320 mM, O UNA COMBINACION DE ARGININA HCl EN UNA CONCENTRACION DE 50 A 150 mM Y ACIDO GLUTAMICO EN UNA CONCENTRACION DE 25 mM A 75 mM COMO ESTABILIZANTE; y D) POLOXAMERO 188 O POLISORBATO 20 EN UNA CONCENTRACION DE 0,25 MG/ML A 0,75 MG/ML COMO SURFACTANTE; DONDE LA FORMULACION TIENE UN PH DE 5 A 6. DICHA FORMULACION ES UTIL PARA EL TRATAMIENTO DEL CANCER PULMONAR DE CELULAS NO PEQUENAS, CARCINOMA UROTELIAL, CANCER DE VEJIGA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198233 | 2015-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181400A1 true PE20181400A1 (es) | 2018-09-07 |
Family
ID=54838201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001077A PE20181400A1 (es) | 2015-12-07 | 2016-12-05 | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11058769B2 (es) |
| EP (2) | EP3747466A1 (es) |
| JP (1) | JP6925337B2 (es) |
| KR (1) | KR20180085801A (es) |
| CN (1) | CN108367072B (es) |
| AR (1) | AR107014A1 (es) |
| AU (1) | AU2016368099C1 (es) |
| BR (1) | BR112018010211A2 (es) |
| CA (1) | CA3007481C (es) |
| CL (1) | CL2018001488A1 (es) |
| CO (1) | CO2018005525A2 (es) |
| CY (1) | CY1123358T1 (es) |
| DK (1) | DK3386541T3 (es) |
| EA (1) | EA201891339A1 (es) |
| ES (1) | ES2823279T3 (es) |
| HK (1) | HK1257781A1 (es) |
| HR (1) | HRP20201573T1 (es) |
| HU (1) | HUE050811T2 (es) |
| IL (1) | IL259563B (es) |
| LT (1) | LT3386541T (es) |
| MX (1) | MX2018006875A (es) |
| MY (1) | MY195681A (es) |
| NZ (1) | NZ743964A (es) |
| PE (1) | PE20181400A1 (es) |
| PH (1) | PH12018500894A1 (es) |
| PL (1) | PL3386541T3 (es) |
| PT (1) | PT3386541T (es) |
| RS (1) | RS61029B1 (es) |
| SA (1) | SA518391743B1 (es) |
| SG (1) | SG11201804758QA (es) |
| SI (1) | SI3386541T1 (es) |
| TW (1) | TWI630917B (es) |
| UA (1) | UA123270C2 (es) |
| WO (1) | WO2017097407A1 (es) |
| ZA (1) | ZA201804534B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6138813B2 (ja) * | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗ｐｄ−ｌ１抗体及びその使用 |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| PT3386541T (pt) | 2015-12-07 | 2020-10-12 | Merck Patent Gmbh | Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab |
| PE20190510A1 (es) | 2016-06-13 | 2019-04-10 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos |
| CN109843324A (zh) | 2016-10-06 | 2019-06-04 | 辉瑞公司 | 用于治疗癌症的avelumab用药方案 |
| BR112019018401A2 (pt) * | 2017-03-06 | 2020-04-07 | Merck Patent Gmbh | formulação aquosa de anticorpo anti-pd-l1 |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| CN114632150B (zh) * | 2017-11-02 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| WO2020060183A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 트라스투주맙 항체 안정화 액체 제제 |
| US20230287122A1 (en) * | 2018-11-29 | 2023-09-14 | Harbour Biomed Therapeutics Limited | Anti-pd-l1 antibody preparation |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| TWI761869B (zh) * | 2019-06-25 | 2022-04-21 | 大陸商信達生物製藥（蘇州）有限公司 | 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途 |
| CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| JP2023506629A (ja) * | 2019-12-13 | 2023-02-17 | サムスン バイオエピス カンパニー リミテッド | 安定した抗ｐｄ－１抗体の薬剤学的製剤 |
| EP4362984A1 (en) | 2021-07-02 | 2024-05-08 | Yale University | Compositions and methods for treating cancers |
| WO2023034864A1 (en) | 2021-08-31 | 2023-03-09 | Yale University | Compositions and methods for treating cancers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI2264043T1 (en) | 2005-09-02 | 2018-01-31 | Glycomimetics, Inc. | HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS |
| CN101584858A (zh) | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| HUE034832T2 (hu) * | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| SG182304A1 (en) * | 2009-12-29 | 2012-08-30 | Hoffmann La Roche | Antibody formulation |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| LT2691112T (lt) * | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
| JP6138813B2 (ja) * | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗ｐｄ−ｌ１抗体及びその使用 |
| CN104169299B (zh) * | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| SI3049441T1 (sl) | 2013-09-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Formulacije protiteles proti PD-L1 |
| CA2926588C (en) * | 2013-10-16 | 2020-07-21 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| KR20170003692A (ko) * | 2014-05-15 | 2017-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 |
| CN105085680A (zh) * | 2014-05-23 | 2015-11-25 | 复旦大学 | 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用 |
| NZ733854A (en) | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| US10945994B2 (en) | 2015-05-14 | 2021-03-16 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body |
| EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| WO2016205277A1 (en) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| PT3386541T (pt) | 2015-12-07 | 2020-10-12 | Merck Patent Gmbh | Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab |
| BR112019018401A2 (pt) | 2017-03-06 | 2020-04-07 | Merck Patent Gmbh | formulação aquosa de anticorpo anti-pd-l1 |
-
2016
- 2016-12-05 PT PT168189850T patent/PT3386541T/pt unknown
- 2016-12-05 PL PL16818985T patent/PL3386541T3/pl unknown
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/da active
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/zh active Active
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/ja active Active
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-05 BR BR112018010211A patent/BR112018010211A2/pt active Search and Examination
- 2016-12-05 ES ES16818985T patent/ES2823279T3/es active Active
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-05 RS RS20201201A patent/RS61029B1/sr unknown
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/es unknown
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 MX MX2018006875A patent/MX2018006875A/es unknown
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 UA UAA201807363A patent/UA123270C2/uk unknown
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en active Application Filing
- 2016-12-05 EA EA201891339A patent/EA201891339A1/ru unknown
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/lt unknown
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/hu unknown
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 KR KR1020187019480A patent/KR20180085801A/ko active Search and Examination
- 2016-12-05 SI SI201630940T patent/SI3386541T1/sl unknown
- 2016-12-06 TW TW105140288A patent/TWI630917B/zh active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/es unknown
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/es unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/es unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/ar unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2019
- 2019-01-04 HK HK19100169.4A patent/HK1257781A1/zh unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/el unknown
- 2020-10-05 HR HRP20201573TT patent/HRP20201573T1/hr unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| PE20181365A1 (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| PE20191815A1 (es) | Formulaciones acuosas estables de adalimumab | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| BR112016015187A2 (pt) | proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| AR103243A1 (es) | Recipiente precargado con toxina botulínica | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| PE20142275A1 (es) | Formulacion de anticuerpo il-17 | |
| EA201992832A1 (ru) | Подкожное введение adamts13 |